All News
The EULAR 2015 Report – Friday and Saturday
These abstracts and presentations were presented last week on the 12th and 13th of June at the EULAR 2015 annual meeting in Rome.
Read ArticleExpanding Global Biosimilar Market
Between 2010 and 2013, $95 billion in branded pharmaceutical patents will have expired, leading to significantly higher sales opportunities for those manufacturing generics and biosimilars.
Read ArticleThe EULAR 2015 Report- Friday
These abstracts and presentations were presented 12 June at the EULAR 2015 annual meeting.
Read ArticleThe EULAR 2015 Report - Wednesday
EULAR 2015 started the afternoon of Wednesday June 10th.
Read ArticleHigh Flare Rates with Drug Withdrawal in JIA
While many adult rheumatologists are able to lessen or withdraw DMARD and biologic therapy in adults, little is known about the success of this practice in pediatric rheumatology clinics.
Read ArticleTofacitinib Equal to Etanercept in Psoriasis, but only at 10 mg bid Dose
A 12-week, phase III, non-inferiority, randomized clinical trial of tofacitinib, etanercept or placebo was conducted in 1106 patients with plaque psoriasis.
Read ArticleNonadherence to Self-Injected Biologics is High
Researchers from the University of Manchester investigated self-reported adherence to biologic treatment in RA and found that 41% of patients were non-adherent to adalimumab therapy at least once, and 23% were nonadherent overall. http://bit.ly/1KA2
Read ArticleMedicare D and Costly Biologics
25% of Medicare beneficiaries with rheumatoid arthritis use high-cost biologics. Yazdany and coworkers have analyzed a national cohort of beneficiaries and compared Medicare part D plans.
Read ArticleAmgen Halts Development of Brodalumab
IL-17 inhibitors are being developed for treatment of psoriasis, psoriatic arthritis and axial spondyloarthritis. Broadalumab has been in phase II & III trials and been developed by a partnership between Amgen and Astra-Zeneca.
Read ArticleRA Sarilumab Trials Meet Primary Endpoints
Three phase III studies of sarilumab (SARIL-RA-TARGET, -EASY and -ASCERTAIN), a fully-human IL6 receptor antibody, have been reported and met primary end points in these pivotal clinical trials.
Read ArticleAmgen & Abbvie Increase the Price of TNF Inhibitors
The manufacturers of the 2 best selling TNF inhibitors, Enbrel and Humira, have announced a 9.9% price increase of May 1st. The current average price of Enbrel is $42,000 per annum.
Read Article
A Microneedle Pill as an Alternative to Injectable Drug
Carl Schoellhammerhas just won the Lemelson-MIT National Collegiate Student Prize for his invention - the microneedle pill.
Read ArticleTanezumab in Osteoarthritis: Data Presented at OARSI
Pooled analyses of the tanezumab (a nerve growth factor inhibitor) phase 3 studies was presented at the 2015 Osteoarthritis Research Society International (OARSI) World Congress.
Read ArticleEconomic Impact of Biosimilars
According to the Federal Trade Commission biosimilars have the potential to save the U.S. healthcare system $250 billion through 2022.
Read ArticleHepatotoxicity and TNF Inhibitors
Hepatic enzyme elevations with TNF inhibitor use is not uncommon.
Read ArticleRA Compliance Undermines Treatment Success
Researchers at MD Anderson Cancer Center in Houston prospectively studied 107 RA patients with regard to oral medication (DMARDs, steroids) adherence. They report that adherence was low, ranging from 58-71% overall.
Read ArticleZoster Risk is Similar Among Different MOA Biologics
The risk of new H zoster infection was studied among nearly 30,000 new biologic starts and compared rates seen with abatacept, adalimumab, rituximab, infliximab, etanercept, tocilizumab, certolizumab or golimumab initiation.
Read ArticleThe Risk of Listeriosis in RA
In the mid-1990s, our Rheumatology Division at the University of Texas Southwestern Medical School became involved with an early trial of a brand new TNF inhibitor.
Read Article